Sep 21, 2016 · Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment Eva S. Thomas. x. results in long-term disease control in patients with taxane-refractory metastatic breast cancer. 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004 (abstr 1070) Cited by: 571. Mar 01, 2013 · Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol.Cited by: 28.
TREATMENT OPTIONS AFTER EXPOSURE TO ANTHRACYCLINE AND TAXANE. Treatment options for recurrent breast cancer and MBC are shown in Figures Figures1, 1,,2 2 and and3 3. 3,22 The choice of therapy for each patient depends on several interlinking factors, including tumor type, disease stage, functional status, and treatment history, particularly any previous adjuvant therapy for early breast Cited by: 78. breast cancer therapy, either after metastatic or adjuvant treatment.3,5 With increasing use of an-thracyclines and taxanes for early breast cancer, fewer effective options are available for patients with metastatic disease.3,4 Capecitabine is com-monly used for the treatment of anthracycline-and/or taxane-pretreated metastatic breast can-.
Jun 01, 2001 · I ntroduction. Metastatic breast cancer (MBC) is essentially incurable with standard therapy, and patients with MBC have a median survival of about 2 years after documentation of metastasis .As a consequence, the goals of treatment are to improve patients' symptoms while trying to maintain (or improve, in certain cases) quality of life.Author: Jean-Marc Nabholtz. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Journal of Clinical Oncology, 2007. Rubi Li. Download with Google Download with Facebook or download with email. Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment.
Ixabepilone has single-agent activity in these patients and has demonstrated synergy with capecitabine in this setting. This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or . Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment. Cancer Chemother Pharmacol. to evaluate the efficacy and safety of ixabepilone plus capecitabine in both anthracycline-pretreated and resistant and taxane-resistant metastatic breast cancer of Chinese women.